Literature DB >> 16948219

[The natural history of multiple sclerosis].

Christian Confavreux1, Sandra Vukusic.   

Abstract

The course of multiple sclerosis (MS) results from the interplay of two clinical processes, relapses and progression. Three main clinical forms may be identified as relapsing-remitting, secondary progressive and primary progressive. The disease appears on average at the age of 30 and follows a remitting or a progressive course in 85% and 15% of the cases, respectively. Initial symptoms are related to an isolated or combined disturbance(s) of the long tracts of the central nervous system, of the brainstem, or of the optic nerve in 70%, 20% and 25% of the cases, respectively. The relapse rate is one relapse on average every other year. After an exacerbating-remitting onset of MS, secondary progression appears after 19 years on average. The median time to reach the landmarks of irreversible disability are 8 years regarding limitation of ambulation, 20 years for walking with a stick, and 30 years for wheel-chair dependency. In fact, MS prognosis is highly variable depending on individuals. All the intermediate types do exist between malignant forms, possibly lethal, and benign forms (circa 30% of the cases) that allow normal daily life. The clinical and paraclinical predictive factors identified so far have been acknowledged statistically. They provide little help however, if any, when an individual is concerned. Recent research has showed that relapses have only a marginal effect, relatively to progression, on the accumulation of irreversible neurological disability. Furthermore, the age when reaching the landmarks of irreversible disability is essentially similar whatever the mode of onset of MS, be it exacerbating-remitting or progressive. In spite of the outstanding clinical polymorphism of MS, a unifying concept of the disease ("complexity vs heterogeneity") can be put forward.

Entities:  

Mesh:

Year:  2006        PMID: 16948219

Source DB:  PubMed          Journal:  Rev Prat        ISSN: 0035-2640


  12 in total

1.  Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.

Authors:  G Balloy; J Pelletier; L Suchet; C Lebrun; M Cohen; P Vermersch; H Zephir; E Duhin; O Gout; R Deschamps; E Le Page; G Edan; P Labauge; C Carra-Dallieres; L Rumbach; E Berger; P Lejeune; P Devos; J-B N'Kendjuo; M Coustans; E Auffray-Calvier; B Daumas-Duport; L Michel; F Lefrere; D A Laplaud; C Brosset; P Derkinderen; J de Seze; S Wiertlewski
Journal:  J Neurol       Date:  2018-07-27       Impact factor: 4.849

2.  Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination.

Authors:  Enrique Garea Rodriguez; Christiane Wegner; Mario Kreutzfeldt; Katharina Neid; Dietmar R Thal; Tanja Jürgens; Wolfgang Brück; Christine Stadelmann; Doron Merkler
Journal:  Acta Neuropathol       Date:  2014-02-25       Impact factor: 17.088

3.  Association of CD58 Polymorphism with Multiple Sclerosis and Response to Interferon ß Therapy in A Subset of Iranian Population.

Authors:  Sara Torbati; Fatemeh Karami; Majid Ghaffarpour; Mahdi Zamani
Journal:  Cell J       Date:  2015-01-13       Impact factor: 2.479

4.  Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective.

Authors:  Julie Chevalier; Catherine Chamoux; Florence Hammès; Annie Chicoye
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

5.  Geographic variations of multiple sclerosis prevalence in France: The latitude gradient is not uniform depending on the socioeconomic status of the studied population.

Authors:  Philippe Ha-Vinh; Stève Nauleau; Marine Clementz; Pierre Régnard; Laurent Sauze; Henri Clavaud
Journal:  Mult Scler J Exp Transl Clin       Date:  2016-02-11

Review 6.  Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.

Authors:  X Armoiry; A Kan; G J Melendez-Torres; R Court; P Sutcliffe; P Auguste; J Madan; C Counsell; A Clarke
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

7.  Rationale and design of a randomized controlled clinical trial of functional electrical stimulation cycling in persons with severe multiple sclerosis.

Authors:  Lara A Pilutti; Robert W Motl; Thomas A Edwards; Kenneth R Wilund
Journal:  Contemp Clin Trials Commun       Date:  2016-05-15

8.  Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.

Authors:  Rafael Arroyo; Denise P Bury; Jennifer D Guo; David H Margolin; Maria Melanson; Nadia Daizadeh; David Cella
Journal:  Mult Scler       Date:  2019-05-30       Impact factor: 6.312

9.  Natural Course of Clinically Isolated Syndrome: A Longitudinal Analysis Using a Markov Model.

Authors:  Yuli Hou; Yujuan Jia; Jingtian Hou
Journal:  Sci Rep       Date:  2018-07-18       Impact factor: 4.379

10.  A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study.

Authors:  Tjalf Ziemssen; Daniela Piani-Meier; Bryan Bennett; Chloe Johnson; Katie Tinsley; Andrew Trigg; Thomas Hach; Frank Dahlke; Davorka Tomic; Chloe Tolley; Mark S Freedman
Journal:  J Med Internet Res       Date:  2020-02-12       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.